Kevin Koch
President and CEO of Edgewise Therapeutics
Kevin Koch
President and CEO of Edgewise Therapeutics
Boulder, Colorado
Overview
Work Experience
President and CEO
2017 - Current
Discovering and developing novel therapies for the treatment of life threatening musculoskeletal disease.
Venture Partner
2016
Senior Vice President, Drug Discovery, Chemical & Molecular Therapeutics
2013 - 2015
Oversight of drug discovery efforts at the company including protein therapeutics and small molecule discovery platforms, the immunology and hematology therapeutic areas, global biomarker discovery and development, external drug discovery collaborations and technology groups to enhance the rate and quality of the drug discovery process including structural biology, HTS, phenotypic screening and chemical proteomics. Chair of Discovery Leadership Governance Team, member of the Sr. Research and Development management team and associated oversight committees for Biogen R&D governance. Evaluation of Business Development Opportunities. Oversight of ~320 R&D professionals.
President and Chief Scientific Officer, Company Founder
1998 - 2013
Fully integrated, structure based design driven, pharmaceutical company discovering and developing small molecule drugs for the treatment cancer, diabetes, pain, respiratory and autoimmune disease. Oversight of all internal and external research as well as early development including translational medicine and clinical pharmacology teams. Array scientists are inventors of 21 compounds that have moved into clinical development via internal and external Array programs. 15 compounds remain in development with 10 in Ph2 studies and 3 molecule sin Phase 3. Member Development Strategy Committee, Chair Research Milestone Group. Member of Joint Research and Development committees for most Array collaborations. Business development. Scientific liaison for all investor interactions including fund-raising for over $500M in public financing and quarterly conference calls. Co-inventor on 4 Array development compounds. Member Board of Directors May, 1998 - November 2012.
President and Chief Scientific Officer
2000 - 2007
Lead research and early development. Built enzymology, high-throughput screening, drug metabolism, pharmacology, toxicology, clinical pharmacology, regulatory, clinical operations and translational medicine teams. Managed external KOL interactions to design clinical trials for Array POC studies. Built chemical process research and development team including GMP manufacture, formulation, drug product QA and QC. Direct budgetary oversight of > 250 R&D professionals. Moved 8 Array internal discovery programs into Ph1/2 clinical studies.
Co-Founder Array BioPharma
1998 - 2000
Co-Founder Array BioPharma. Developed business plan providing a small molecule discovery platform (combinatorial chemistry, medicinal chemistry, protein crystallography, computational chemistry, cell biology) to genomics and pharmaceutical companies growing company from 25 original FTE to ~125 FTE. Drove development of first integrated electronic data capture platform for research in industry. Defined scientific ladder, performance evaluation, organizational structure and strategic goals to optimize the discovery research culture to achieve high productivity. Scientific lead on all Business development interaction. Scientific and strategic lead in public offering 11/2000.
Associate Director, Medicinal Chemistry
1995 - 1998
Protease Inhibitor and New Technologies group
Senior Research Investigator
1993 - 1995
Project Coordinator: Immunology and Cell Adhesion
Inventor
1988 - 1995
Inventor two LTB4 antagonists evaluated in Ph1/2 studies Development candidate nomination for transplantation
Senior Research Scientist
1991 - 1993
Project Coordinator: Immunology
Research Scientist
1988 - 1991
Associate Scientist, Process Research
1983 - 1984